Studies have already shown that glibenclamide, a sulfonylurea used for the treatment of non-insulin-dependent diabetes mellitus (type 2 diabetes), has the ability to inhibit PEPT1 and PEPT2-mediated Gly-Sar uptake with Ki values of 25 μM and 7.8 μM, respectively [27]. Here, SLC15A2 is linked to type 2 diabetes mellitus.